Evidence map›Paper›PMID 40234378›Full record

ArticleCell death & disease2025

VRK1 promotes epithelial-mesenchymal transition in hepatocellular carcinoma mediated by SNAI1 via phosphorylating CHD1L.

Jing Li, Zan Song, Xue Dong, Leilei Li, Xinyu Gu, Kailing Zhang, Zhicheng Zhang, Yu Li, Zhili Fan, Hao Dong and 5 more

Abstract read
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jing LiInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.ORCID http://orcid.org/0009-0005-8758-6597
Zan SongInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Xue DongInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Leilei LiInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Xinyu GuInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Kailing ZhangInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Zhicheng ZhangInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Yu LiInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Zhili FanInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Hao DongInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Ying LiuInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Mengfei LiuInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Huiqing ZhangThe Department of Gastrointestinal Medical Oncology, JXHC Key Laboratory of Tumor Microenvironment and Immunoregulation, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China. huiqingzhang@outlook.com.ORCID http://orcid.org/0000-0001-8915-0563
Wu LiuInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. wuliu@sdu.edu.cn.ORCID http://orcid.org/0000-0001-6259-3049
Tao ZhangInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. zhangtao@sdu.edu.cn.ORCID http://orcid.org/0009-0002-2705-1070

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82104218Taishan Scholar Foundation of Shandong Province TSQN201909033
6 · The paper itself

Abstract

Vaccinia-related kinase 1 (VRK1) is involved in numerous cellular processes, including DNA repair, cell cycle and cell proliferation. However, its roles and molecular mechanism underlying the progression of hepatocellular carcinoma (HCC) are yet largely unexplored. Here, we demonstrated that VRK1 expression is elevated in HCC tumor tissues, which is associated with high tumor stage and poor prognosis in HCC patients. In vitro and in vivo experiments manifested that VRK1 overexpression significantly promotes cell proliferation, colony formation, migration and tumor growth of HCC by inducing epithelial-mesenchymal transition (EMT) program. Mechanistically, immunoprecipitation combined with mass spectrometry analysis determined that VRK1 interacts with CHD1L, which mediates the phosphorylation of CHD1L at serine 122 site. RNA-seq revealed that one of the key downstream target genes of VRK1 is SNAI1, by which VRK1 promotes EMT process and HCC progression. Furthermore, VRK1 upregulates SNAI1 expression through phosphorylating CHD1L. In conclusion, these findings suggested that VRK1/CHD1L/SNAI1 axis acts as a cancer-driving pathway to promote the proliferation and EMT of HCC, indicating that targeting VRK1 may be an attractive therapeutic strategy of HCC.

Indexed as

Carcinoma, HepatocellularDNA-Binding ProteinsDNA HelicasesEpithelial-Mesenchymal TransitionIntracellular Signaling Peptides and ProteinsLiver NeoplasmsProtein Serine-Threonine KinasesSnail Family Transcription FactorsAnimalsCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMaleCHD1L protein, humanDNA-Binding ProteinsDNA HelicasesIntracellular Signaling Peptides and ProteinsProtein Serine-Threonine KinasesSNAI1 protein, humanSnail Family Transcription FactorsVRK1 protein, human

Identifiers

PMID40234378
PMCPMC12000354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.